Press Release

Kubota Vision Announces Issuance of Patents

Seattle (May 8, 2024) — Kubota Vision Inc. ("Kubota Vision" or the "Company"), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the issuance of patents covering eyeMO[*1] and Kubota Glass technology from the U.S. Patent and Trademark Office, assigned to the Company, adding strength to the Company's intellectual property position.

(1) Title of the invention: SYSTEM AND METHOD FOR OPTICAL COHERENCE TOMOGRAPHY[*2] A-SCAN DECURVING

Abstract: An OCT system for measuring a retina as part of an eye health monitoring and diagnosis system. The OCT system includes an OCT interferometer, where the interferometer comprises a light source or measurement beam and a scanner for moving the beam on the retina of a patient's eye, and a processor configured to execute instructions to cause the scanner to move the measurement beam on the retina in a scan pattern. Measurement data may be processed using a decurving process to enhance the resolution of the ILM layer and provide improved determinations of retinal thickness.

Issuance country: United States of America

Patent number: US 11,974,807

Date of Patent: May 7, 2024

Assignee: Acucela Inc.

[*1] eyeMO is a product name for the Patient Based Ophthalmology Suite (PBOS).

[*2] Optical Coherence Tomography (OCT) is a non-invasive tool that uses light waves to take cross-section pictures of the retina.

(2) Title of the invention: ELECTRO-SWITCHABLE SPECTACLES FOR MYOPIA TREATMENT

Abstract: An apparatus to treat refractive error of an eye comprises an electroactive component configured to switch between a light scattering or optical power providing configuration to treat refractive error of the eye and a substantially transpar-ent configuration to allow normal viewing. The electroactive component can be located on the lens away from a central axis of the lens to provide light to a peripheral region of the retina to decrease the progression of myopia. The electro-active component can be located on the lens away from the central axis of the lens in order for the wearer to view objects through an optical zone while the electroactive component scatters light. The electroactive component can be config-ured to switch to the substantially transparent configuration to allow light to pass through the electroactive component and to allow the lens to refract light to correct vision and allow normal viewing through the lens.

Issuance country: United States of America

Patent number: US 11,971,615

Date of Patent: April 30, 2024

Assignee: Acucela Inc.

About eyeMO

eyeMO is a low cost, home-based, ophthalmic self-monitoring OCT device. This small handheld device addresses needs in mobile Health (mHealth[*3]) applications for self-monitoring of retina health by patients in the home and in remote field locations. eyeMO aims to improve ophthalmic treatment outcomes in patients diagnosed with and treated for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other neovascular retinal diseases. eyeMO is being designed to detect nascent disease progression and support patient re-treatment prior to irreversible vision loss due to disease progression. Key features are low cost and a patient-friendly design, to be used directly by patients at home. eyeMO is being designed to capture changes in retinal anatomy. Network connectivity and cloud-based technologies are used to alert the patients and their physicians of disease progression and re-treatment needs.

[*3] mHealth refers to the usage of mobile communications technology and devices to enhance access to healthcare information, improve distribution of routine and emergency health services, and provide diagnostic services.

About Kubota Glass™ Technology

Kubota Glass technology works to aid vision in myopia by projecting specially focused images generated using micro-LEDS in the peripheral visual field. The Company has been conducting and publishing research evaluating the device for the management of myopia. Kubota Glass technology leverages nanotechnology in its electronic glasses-based illumination device and seeks to help manage myopia by providing specially focused illumination while maintaining high-quality central vision.

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.
https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial

potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (https://www.kubotaholdings.co.jp/en/ir/) and on the SEC's website (http://www.sec.gov).

Media and Investor Relations Contact:

Press and Media Inquiries
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp

# # #